The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.

Learn more about:
Related Clinical Trial
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy Impact of GH Measurements on GHD Diagnosis Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents Constructing an Insulin-Like Growth Factor-based Prediction Model Peripheral Metabolic Effects of Somatostatin Chromosome 18 Clinical Research Center The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids. An Observational Study on Treatment Compliance by Children Treated With Growth Hormone A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Safety and Efficacy of Long-term Somatropin Treatment in Adults Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle Genotropin Study Assessing Use of Injection Pen Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy Treatment of Children With Insufficient Secretion of Growth Hormone Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Inter-Assay Growth Hormone and IGF-I Variability A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy Easypod United States User Trial National Cooperative Growth Study in CKD Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients Practicability and Acceptability of Stylomax® in Children Growth Hormone’s Effect on the Cardiovascular System Exploring Interactions Between Growth Hormone and the Microbiome Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children Phase 1 Safety Study of ALRN-5281 in Healthy Subjects Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Growth Hormone and Chromosome 18q- and Abnormal Growth An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Study of TV-1106 in Growth Hormone-Deficient Adults Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates Gene Expression in Monocytes of Growth Hormone Deficient Children Study of Pituitary Size and Function in Familial Dwarfism of Sindh Adipocyte Function and Somtropin Deficiency Sustained Release Formulation of Somatropin (rDNA Origin)for Injection Molecular Basis of the Growth Axis in Short Stature Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States The Effects of Growth Hormone (GH) on Lipid Depots The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing Metabolic Endocrinology and Growth Hormone in Adults Growth Hormone Treatment of Young Growth Hormone-Deficient Adults Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) rhGH Therapy on Hepatic Drug Metabolism Skeletal Muscle Effects of GH in Boys Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas Adipose Tissue and Serum Inflammation in GH Deficiency Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Brief Title

The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.

Official Title

The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.

Brief Summary

      This study aims at assessing the effect of standardized dietary fat load and short-term
      aerobic exercise on systemic lipolysis, flexibility and partitioning of ectopic fat stores
      (intramyocellular = IMCL, intrahepatocellular = IHCL, intramyocardial lipids = IMCaL) in
      relation to FFA in endurance trained athletes and hypopituitary patients compared to
      sedentary healthy control subjects.

      Exercise is a powerful stimulation for growth hormone (GH) secretion in health. A
      standardised exercise test can, therefore, be discriminative for the diagnosis of
      GH-deficiency in adults. This will be assessed.

      Hypothesis (ectopic fat stores)

        1. Ectopic fats stores are flexible fuel stores and are influenced by diet and physical
           activity.FFA availability may play an important regulatory role.

        2. There is a tissue specific partitioning of triglycerides and/or FFA among non-adipose
           organs after fat load and physical exercise

        3. The flexibility of ectopic fat stores is related to insulin sensitivity

        4. Lipolytic and anti-lipolytic hormones are critical for regulating FFA availability (at
           rest or during exercise) and therefore also for the regulation of ectopic fat stores.

        5. GH is a lipolytica hormone. Lack of GH in adulthood is related to decreased FFA
           availability thereby influencing ectopic lipid stores Hypothesis diagnosis of GHD

        6. A short intensive physical exercise shows a good discriminative power to diagnose GHD.
    

Detailed Description

      Background

      Obesity, in particular visceral obesity, is associated with impaired insulin action on target
      tissues (insulin resistance or metabolic syndrome) that, in turn, is related to an increased
      risk for cardiovascular mortality and morbidity. Pathophysiological mechanism remains
      unclear. Interventions in patients with impaired glucose tolerance/impaired fasting glucose
      have consistently demonstrated that by increasing physical activity and reducing calorie
      intake the risk to convert to frank type 2 diabetes is decreased, even more efficiently than
      by early medical therapy with metformin.

      Physically inactive and overweight subjects do not only store the excess of fat in the
      intra-abdominal or subcutaneous department but also in non-adipose tissue (="ectopic"
      tissues), such also skeletal muscle, liver and myocardium, also called intramyocellular
      lipids (IMCL), intrahepatocellular lipids (IHCL) and intramyocardial lipids (IMCaL).This
      ectopic lipid accumulation occurs either by increased free fatty acids (FFA) uptake, increase
      synthesis in the involved tissues or reduced FFA oxidation.

      The relative contribution of these factors to ectopic lipid accumulation varies in different
      physiological conditions (i.e. physical exercise, fasting, postprandial condition) and in
      different tissues. In addition, it may be influenced by hormones that regulate lipid
      metabolism. There is increasing evidence that ectopic fat and its intermediate metabolites
      interfere with insulin signalling, thereby contributing to the impaired insulin action on
      target tissues such as liver and skeletal muscle. It has been well showed that high fat
      oxydation capacity allows to keep a lower lipolytic activity and therefore low levels of
      lipolyse degradation products. Strong evidence is accumulating that these intermediates
      interact with insulin signalling finally resulting in insulin resistance.

      There is still scarce data about the behaviour of ectopic fat stores in the presence of
      positive(nutritional fat excess) or negative energy balance (physical activity) and the role
      of hormones in regulating these fat depots.

      Additionally,we have previously shown that GH values obtained during a 2h standardized
      aerobic exercise of moderate intensity revealed a high diagnostic accuracy in predicting
      severe GHD in adult individuals. Whether a shorter exercise on higher intensity may lead to
      comparable results has to be assessed.

      Objective

      The study aims to comprehensively assess the flexibility and partitioning of ectopic fat
      deposition and to define the role of relevant hormones (especially GH and insulin) in
      relation to the availability of FFAs as well as their role in the process of ectopic fat
      deposition and consumption. Another objective is to investigate the role of a standardized
      fat load and aerobic exercise on IMCaL.

      Methods

      Using the two-step hyperinsulinaemic-euglycaemic clamp technique hepatic and peripheral
      insulin sensitivity is assessed.

      Lipid depots (skeletal muscle and liver) are repeatedly measured by MR-spectroscopy,
      subcutaneous and visceral fat mass by whole body MR-imaging.

      Exercise capacity ist measured on a bicycle (incl. spiroergometry). Counterregulatory
      hormones, glucose and free fatty acids are measured during a 2h physical exercise at 50-60
      VO2max.

      Blood samples to evaluate GH will be taken immediately before and after the Vo2 max-test, as
      well as 15, 30 and 45minutes after the end of the exercise test.
    


Study Type

Observational


Primary Outcome

Flexibility of IMCaL, IMCL and IHCL (fat load and exercise)

Secondary Outcome

 Determination of visceral fat mass by MRI

Condition

Ectopic Lipids

Intervention

Fat diet

Study Arms / Comparison Groups

 1
Description:  Endurance trained athletes: minimal >50 mlO2/KG body weight

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Dietary Supplement

Estimated Enrollment

30

Start Date

August 2011

Completion Date

May 2014

Primary Completion Date

May 2014

Eligibility Criteria

        Inclusion Criteria:

          -  Male and female patients >18 years old

          -  Capable to exercise for 120 minutes on a treadmill

          -  Willingness to participate in the study and to give written consent.

          -  Normal ECG during ergometry

          -  Specific for Athletes: VO2max> 50 ml/kg/min

          -  Specific for GHD patients: no GH substitution in the last 6 months

          -  Specific for sedentary controls: Matched the GHD patients for age, gender, BMI and
             waist

        Exclusion Criteria

          -  Abnormal liver or renal function

          -  Active neoplasia

          -  Severe cardiovascular disease (unstable coronary artery disease, heart failure NYHA
             III-IV)

          -  Haemophilia

          -  Inability to exercise

          -  Contraindications to exposure to a 3 T magnetic field

          -  Abnormal ECG during ergometry

          -  Women in childbearing age unless on a continuous contraceptive therapy or surgically
             sterilized

          -  Depression, psychosis and other severe personality disorders

          -  Pregnant women

          -  Excessive alcohol consumption (>60g/d) or drug abuse
      

Gender

All

Ages

18 Years - 80 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Emanuel Christ, Prof. Dr med. MD, PhD, , 

Location Countries

Switzerland

Location Countries

Switzerland

Administrative Informations


NCT ID

NCT01467193

Organization ID

234/10



Study Sponsor

University Hospital Inselspital, Berne

Collaborators

 Swiss National Science Foundation

Study Sponsor

Emanuel Christ, Prof. Dr med. MD, PhD, Principal Investigator, Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Bern


Verification Date

October 2018